Eli Lilly acquired global rights to MeiraGTx’s AAV‑AIPL1 gene therapy for Leber congenital amaurosis 4 (LCA4), paying $75 million up front and taking on programs expected to file for U.S. and European approvals. The deal expands Lilly’s genetic‑medicines slate following recent moves in ocular gene therapy and RNA therapeutics. Lilly framed the purchase as part of a broader strategy to build a genetic medicines franchise in ophthalmology. The asset is in late stages with regulatory filings anticipated; the agreement gives Lilly global commercialization control and accelerates its entry into ultra‑rare inherited retinal disease markets.